ACXP 8-K: Board change
Acurx Pharmaceuticals
Filed with the SEC on · accession 0001104659-26-130615
ACXP filed a 8-K (current report) with the SEC on Nov 20, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Acurx Pharmaceuticals announced that board member Thomas Harrison, who served on the Board of Directors since 2021, unexpectedly passed away on November 18, 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for ACXP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ACXP?
Click hereFrequently asked questions
What did ACXP file with the SEC on Nov 20, 2026?
ACXP filed a 8-K (Board change). Acurx Pharmaceuticals announced that board member Thomas Harrison, who served on the Board of Directors since 2021, unexpectedly passed away on November 18, 2026.
What does a board change mean for ACXP stock?
Not always. A planned retirement with a successor is usually calm; a sudden departure “effective immediately”, especially of a CFO or near results, often worries investors.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other ACXP SEC filings
Get alerts when ACXP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days